These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 36309305)
1. Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. Zhu Y; Yang X; Xun J; Liu J; Wen Q; Lin Y; Shen X; Chen J; Yuan S; Zhao X; Wang J; Pan H; Yang J; Liang Z; Liang Y; Lin Q; Liang H; Li M; Liu J; Shen Y; Zhang X; Wang P; Lu D; Yin C; Xu J; Jiang S; Lu H; Zhu H Virol Sin; 2022 Dec; 37(6):831-841. PubMed ID: 36309305 [TBL] [Abstract][Full Text] [Related]
2. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
4. The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. Yang X; Zhu Y; Xun J; Liu J; Wen Q; Lin Y; Shen X; Chen J; Yuan S; Zhao X; Wang J; Pan H; Yang J; Liang Z; Liang Y; Lin Q; Liang H; Zhou C; Jin L; Xie W; Liu J; Lu D; Ying T; Shen Y; Zhang X; Xu J; Yin C; Wang P; Jiang S; Lu H; Zhu H iScience; 2022 Sep; 25(9):105016. PubMed ID: 36062074 [TBL] [Abstract][Full Text] [Related]
5. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594 [No Abstract] [Full Text] [Related]
6. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880 [TBL] [Abstract][Full Text] [Related]
7. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination. Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W Front Immunol; 2022; 13():967051. PubMed ID: 36159863 [TBL] [Abstract][Full Text] [Related]
9. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867 [TBL] [Abstract][Full Text] [Related]
10. Comparative Pharmacological Efficacy of COVID-19 Vaccines against the Variants of Concerns (VOCs) of SARS-CoV-2: Recent Clinical Studies on Booster Dose. Zhao D; Wang X; Liu J; Au C; Basavaraj V; Sri CD; Nikolenko VN; Beeraka NM; Shivaprakash P; Fan R Curr Pharm Biotechnol; 2023; 24(13):1603-1612. PubMed ID: 36843370 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Kaabi NA; Yang YK; Du LF; Xu K; Shao S; Liang Y; Kang Y; Su JG; Zhang J; Yang T; Hussein S; ElDein MS; Yang SS; Lei W; Gao XJ; Jiang Z; Cong X; Tan Y; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Hou JW; Lei ZH; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM Nat Commun; 2022 Jun; 13(1):3654. PubMed ID: 35760812 [TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P Front Immunol; 2022; 13():981693. PubMed ID: 36225911 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041 [TBL] [Abstract][Full Text] [Related]
14. Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants. Xie Y; Liu L; Wang J; Zheng Y; Luo C; Ni W; He Z; Zhao X; Liu Y; He Y; Zheng S; Li L; Liu Z Front Immunol; 2022; 13():975533. PubMed ID: 36248883 [TBL] [Abstract][Full Text] [Related]
15. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Yu X; Wei D; Xu W; Liu C; Guo W; Li X; Tan W; Liu L; Zhang X; Qu J; Yang Z; Chen E Nat Commun; 2022 Apr; 13(1):1788. PubMed ID: 35379815 [TBL] [Abstract][Full Text] [Related]
17. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal neutralization activities on authentic Omicron variant provided by three doses of BBIBP-CorV vaccination during one year. Lai DY; Xue JB; He P; Jiang HW; Li Y; Ma ML; Hong W; Yu JP; Wei HP; Tao SC Proteomics; 2023 Jan; 23(2):e2200306. PubMed ID: 36205637 [TBL] [Abstract][Full Text] [Related]
20. Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. Zhang M; Gong Y; Jiao S Future Virol; 2022 Mar; ():. PubMed ID: 35492429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]